Trump reiterates that the president has the authority to decide whether to impose tariffs
BlockBeats News, November 9 — Trump reiterated in a post that the U.S. President has the authority to decide whether to impose tariffs: "So, let's make this clear? The President of the United States is allowed (and Congress has fully approved!) to stop all trade with foreign countries (which is much more troublesome than imposing tariffs!), and can also grant licenses to foreign countries, but cannot impose simple tariffs on foreign countries, even for national security reasons. This was never the intention of our great Founding Fathers! This is simply ridiculous! Other countries can impose tariffs on us, but we can't impose tariffs on them? That's their dream! Companies are flocking to the United States entirely because of tariffs. Hasn't the U.S. Supreme Court been informed of this? What on earth is going on?"
This Wednesday, the U.S. Supreme Court held oral arguments on the legality of Trump's large-scale imposition of reciprocal tariffs. In addition to the liberal justices, several conservative justices also questioned the legality of Trump's tariffs. Chief Justice John Roberts stated that Trump's tariffs are a tax on Americans, which has always been a core power of Congress. Of the three justices appointed by Trump, Neil Gorsuch and Amy Coney Barrett also raised skeptical questions and delved into the arguments of the tariff opponents. Conservative justices hold a majority in the Supreme Court, with a 6:3 ratio. The Supreme Court may announce its decision in December.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

